Charles Rhyee
Stock Analyst at TD Cowen
(1.97)
# 3,092
Out of 5,111 analysts
64
Total ratings
43.18%
Success rate
-8.01%
Average return
Main Sectors:
Stocks Rated by Charles Rhyee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GDRX GoodRx Holdings | Maintains: Buy | $7 → $6 | $2.75 | +118.18% | 8 | Nov 10, 2025 | |
| CRL Charles River Laboratories International | Maintains: Buy | $205 → $197 | $195.60 | +0.72% | 6 | Nov 10, 2025 | |
| COR Cencora | Maintains: Buy | $350 → $400 | $342.36 | +16.84% | 1 | Nov 10, 2025 | |
| CI The Cigna Group | Maintains: Buy | $387 → $333 | $276.00 | +20.65% | 1 | Nov 4, 2025 | |
| CVS CVS Health | Maintains: Buy | $99 → $100 | $78.18 | +27.91% | 1 | Nov 3, 2025 | |
| CAH Cardinal Health | Maintains: Buy | $183 → $225 | $197.56 | +13.89% | 3 | Nov 3, 2025 | |
| OPCH Option Care Health | Maintains: Hold | $30 → $27 | $32.95 | -18.06% | 2 | Nov 3, 2025 | |
| IQV IQVIA Holdings | Downgrades: Hold | $206 → $215 | $221.57 | -2.97% | 2 | Nov 3, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Hold | $183 → $172 | $182.48 | -5.74% | 5 | Oct 24, 2025 | |
| MEDP Medpace Holdings | Maintains: Sell | $356 → $462 | $551.23 | -16.19% | 6 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $297 → $380 | $217.77 | +74.50% | 4 | Oct 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $830 → $864 | $809.73 | +6.70% | 4 | Sep 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $23 → $25 | $16.06 | +55.67% | 3 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $9 → $8 | $7.36 | +8.70% | 6 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $5 | $3.55 | +40.85% | 2 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $100 → $50 | $4.64 | +977.59% | 3 | Mar 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $56 | $12.21 | +358.64% | 2 | Oct 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $360 → $280 | $12.04 | +2,225.58% | 3 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $50 | $4.05 | +1,134.57% | 2 | Jun 21, 2022 |
GoodRx Holdings
Nov 10, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $2.75
Upside: +118.18%
Charles River Laboratories International
Nov 10, 2025
Maintains: Buy
Price Target: $205 → $197
Current: $195.60
Upside: +0.72%
Cencora
Nov 10, 2025
Maintains: Buy
Price Target: $350 → $400
Current: $342.36
Upside: +16.84%
The Cigna Group
Nov 4, 2025
Maintains: Buy
Price Target: $387 → $333
Current: $276.00
Upside: +20.65%
CVS Health
Nov 3, 2025
Maintains: Buy
Price Target: $99 → $100
Current: $78.18
Upside: +27.91%
Cardinal Health
Nov 3, 2025
Maintains: Buy
Price Target: $183 → $225
Current: $197.56
Upside: +13.89%
Option Care Health
Nov 3, 2025
Maintains: Hold
Price Target: $30 → $27
Current: $32.95
Upside: -18.06%
IQVIA Holdings
Nov 3, 2025
Downgrades: Hold
Price Target: $206 → $215
Current: $221.57
Upside: -2.97%
ICON Public Limited Company
Oct 24, 2025
Maintains: Hold
Price Target: $183 → $172
Current: $182.48
Upside: -5.74%
Medpace Holdings
Oct 24, 2025
Maintains: Sell
Price Target: $356 → $462
Current: $551.23
Upside: -16.19%
Oct 7, 2025
Upgrades: Buy
Price Target: $297 → $380
Current: $217.77
Upside: +74.50%
Sep 24, 2025
Maintains: Buy
Price Target: $830 → $864
Current: $809.73
Upside: +6.70%
Nov 11, 2024
Maintains: Hold
Price Target: $23 → $25
Current: $16.06
Upside: +55.67%
Oct 31, 2024
Maintains: Hold
Price Target: $9 → $8
Current: $7.36
Upside: +8.70%
May 3, 2023
Maintains: Outperform
Price Target: $4 → $5
Current: $3.55
Upside: +40.85%
Mar 23, 2023
Downgrades: Market Perform
Price Target: $100 → $50
Current: $4.64
Upside: +977.59%
Oct 20, 2022
Maintains: Outperform
Price Target: $70 → $56
Current: $12.21
Upside: +358.64%
Aug 16, 2022
Maintains: Outperform
Price Target: $360 → $280
Current: $12.04
Upside: +2,225.58%
Jun 21, 2022
Maintains: Outperform
Price Target: $48 → $50
Current: $4.05
Upside: +1,134.57%